RGD peptide targeted lipid-coated nanoparticles for combinatorial delivery of sorafenib and quercetin against hepatocellular carcinoma

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Oliveri RS, Wetterslev J, Gluud C. Hepatocellular carcinoma. Lancet 2012;380:470; author reply 470–1.
   PubMed Web of Science ®Google Scholar
• Bondì ML, Azzolina A, Craparo EF, et al. Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells. J Nanobiotechnol 2014;12:21.
   PubMed Web of Science ®Google Scholar
• Cervello M, McCubrey JA, Cusimano A, et al. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012;3:236–60.
   PubMed Web of Science ®Google Scholar
• Singh S, Singh PP, Roberts LR, Sanchez W. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2014;11:45–54.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835–44.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293–300.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34.
   PubMed Web of Science ®Google Scholar
• Rigalli JP, Ciriaci N, Arias A, et al. Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on Sorafenib cytotoxicity. PLoS One 2015;10:e0119502.
   PubMed Web of Science ®Google Scholar
• Cao H, Wang Y, He X, et al. Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma. Mol Pharm 2015;12:922–31.
   PubMed Web of Science ®Google Scholar
• Wang JL, Xi Y, Liu YL, et al. Combination of targeted PDT and anti-VEGF therapy for rat CNV by RGD-modified liposomal photocyanine and sorafenib. Invest Ophthalmol Vis Sci 2013;54:7983–9.
   PubMed Web of Science ®Google Scholar
• He C, Lu J, Lin W. Hybrid nanoparticles for combination therapy of cancer. J Control Release 2015;pii:S0168–S3659(15)30130–9.
   Google Scholar
• Formica JV, Regelson W. Review of the biology of Quercetin and related bioflavonoids. Food Chem Toxicol 1995;33:1061–80.
   PubMed Web of Science ®Google Scholar
• Guo D, Wu C, Li J, et al. Synergistic effect of functionalized nickel nanoparticles and quercetin on inhibition of the SMMC-7721 cells proliferation. Nanoscale Res Lett 2009;4:1395–402.
   PubMed Web of Science ®Google Scholar
• Wong CC, Akiyama Y, Abe T, et al. Carrier-mediated transport of quercetin conjugates: involvement of organic anion transporters and organic anion transporting polypeptides. Biochem Pharmacol 2012;84:564–70.
   PubMed Web of Science ®Google Scholar
• Zhao JL, Zhao J, Jiao HJ. Synergistic growth-suppressive effects of quercetin and cisplatin on HepG2 human hepatocellular carcinoma cells. Appl Biochem Biotechnol 2014;172:784–91.
   PubMed Web of Science ®Google Scholar
• Bagad M, Khan ZA. Poly(n-butylcyanoacrylate) nanoparticles for oral delivery of quercetin: preparation, characterization, and pharmacokinetics and biodistribution studies in Wistar rats. Int J Nanomed 2015;10:3921–35.
   PubMed Web of Science ®Google Scholar
• Maurya AK, Vinayak M. Anticarcinogenic action of quercetin by downregulation of phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) via induction of p53 in hepatocellular carcinoma (HepG2) cell line. Mol Biol Rep 2015;42:1419–29.
   PubMed Web of Science ®Google Scholar
• Sugahara KN, Teesalu T, Karmali PP, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010;328:1031–5.
   PubMed Web of Science ®Google Scholar
• Wang CF, Mäkilä EM, Kaasalainen MH, et al. Copper-free azide-alkyne cycloaddition of targeting peptides to porous silicon nanoparticles for intracellular drug uptake. Biomaterials 2014;35:1257–66.
   PubMed Web of Science ®Google Scholar
• Liao YT, Liu CH, Yu J, Wu KC. Liver cancer cells: targeting and prolonged-release drug carriers consisting of mesoporous silica nanoparticles and alginate microspheres. Int J Nanomed 2014;9:2767–78.
   PubMed Web of Science ®Google Scholar
• Zeng S, Wu F, Li B, et al. Synthesis, characterization, and evaluation of a novel amphiphilic polymer RGD-PEG-Chol for target drug delivery system. Sci World J 2014;2014:546176.
   Google Scholar
• Gao DY, Lin TT, Sung YC, et al. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer. Biomaterials 2015;67:194–203.
   PubMed Web of Science ®Google Scholar
• Pimple S, Manjappa AS, Ukawala M, Murthy RS. PLGA nanoparticles loaded with etoposide and quercetin dihydrate individually: in vitro cell line study to ensure advantage of combination therapy. Cancer Nanotechnol 2012;3:25–36.
   PubMedGoogle Scholar
• Kim do H, Kim MD, Choi CW, et al. Antitumor activity of sorafenib-incorporated nanoparticles of dextran/poly(dl-lactide-co-glycolide) block copolymer. Nanoscale Res Lett 2012;7:91. DOI: 10.1186/1556-276X-7-91.
   PubMed Web of Science ®Google Scholar
• Mezghrani O, Tang Y, Ke X, et al. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin. Int J Pharm 2015;478:553–68.
   PubMed Web of Science ®Google Scholar
• Kheiri Manjili H, Ma'mani L, Tavaddod S, et al. D, L-sulforaphane loaded Fe3O4@ gold core shell nanoparticles: a potential sulforaphane delivery system. PLoS One 2016;11:e0151344.
   PubMed Web of Science ®Google Scholar
• Liu C, Liu F, Feng L, et al. The targeted co-delivery of DNA and doxorubicin to tumor cells via multifunctional PEI-PEG based nanoparticles. Biomaterials 2013;34:2547–64.
   PubMed Web of Science ®Google Scholar
• Birdhariya B, Kesharwani P, Jain NK. Effect of surface capping on targeting potential of folate decorated poly (propylene imine) dendrimers. Drug Dev Ind Pharm 2015;41:1393–9.
   PubMed Web of Science ®Google Scholar
• Singh R, Kesharwani P, Mehra NK, et al. Development and characterization of folate anchored Saquinavir entrapped PLGA nanoparticles for anti-tumor activity. Drug Dev Ind Pharm 2015;41:1888–901.
   PubMed Web of Science ®Google Scholar
• Aguilar-Rosas I, Alcalá-Alcalá S, Llera-Rojas V, Ganem-Rondero A. Preparation and characterization of mucoadhesive nanoparticles of poly (methyl vinyl ether-co-maleic anhydride) containing glycyrrhizic acid intended for vaginal administration. Drug Dev Ind Pharm 2015;41:1632–9.
   PubMed Web of Science ®Google Scholar
• Jeong YI, Kim DG, Jang MK, et al. All-trans retinoic acid release from surfactant-free nanoparticles of poly(DL-lactide-co-glycolide). Macromol Res 2008;16:717–24.
   Web of Science ®Google Scholar
• Cai LL, Liu P, Li X, et al. RGD peptide-mediated chitosan-based polymeric micelles targeting delivery for integrin-overexpressing tumor cells. Int J Nanomed 2011;6:3499–508.
   PubMed Web of Science ®Google Scholar
• Jafarieh O, Md S, Ali M, et al. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting. Drug Dev Ind Pharm 2015;41:1674–81.
   PubMed Web of Science ®Google Scholar
• Ledet G, Pamujula S, Walker V, et al. Development and in vitro evaluation of a nanoemulsion for transcutaneous delivery. Drug Dev Ind Pharm 2014;40:370–9.
   PubMed Web of Science ®Google Scholar
• Singh SK, Banala VT, Gupta GK, et al. Development of docetaxel nanocapsules for improving in vitro cytotoxicity and cellular uptake in MCF-7 cells. Drug Dev Ind Pharm 2015;41:1759–68.
   PubMed Web of Science ®Google Scholar
• Hu H, Liu D, Zhao X, et al. Preparation, characterization, cellular uptake and evaluation in vivo of solid lipid nanoparticles loaded with cucurbitacin B. Drug Dev Ind Pharm 2013;39:770–9.
   PubMed Web of Science ®Google Scholar
• Colombo S, Cun D, Remaut K, et al. Mechanistic profiling of the siRNA delivery dynamics of lipid-polymer hybrid nanoparticles. J Control Release 2015;201:22–31.
   PubMed Web of Science ®Google Scholar